There are numerous exceptions. Reverse splits are a disaster when a company has no revenue, like with a biotech in Phase Whatever testing that thinks it will get them on NASDAQ and attract institutional interest.. Even then, it's not always trouble, but, I agree, usually is if the company share price can then be manipulated downward, again. The big difference is that SFOR has revenue and simply needs share restructuring. That said, I think a share buy back program with law suit proceeds is the way to go.